Insulin Sensitizers and Cardiovascular Risk Factors in PCOS
Insulin Sensitizers and Cardiovascular Risk Factors in PCOS
Much remains to be understood about the underlying IR and pathophysiology of PCOS. Adequately powered longitudinal studies with sufficient sample sizes are required to prove any definite longer-term beneficial effects of insulin sensitizers, and years of follow-up will be required to obtain conclusive evidence on cardiovascular outcomes with the use of insulin sensitizers. Diet and exercise remain the first line of treatment in women with PCOS, with metformin remaining the most prescribed drug when lifestyle changes are insufficient.
Conclusion
Much remains to be understood about the underlying IR and pathophysiology of PCOS. Adequately powered longitudinal studies with sufficient sample sizes are required to prove any definite longer-term beneficial effects of insulin sensitizers, and years of follow-up will be required to obtain conclusive evidence on cardiovascular outcomes with the use of insulin sensitizers. Diet and exercise remain the first line of treatment in women with PCOS, with metformin remaining the most prescribed drug when lifestyle changes are insufficient.